Cytotoxic Evaluation of Doxorubicin Combination with Baicalein and Resveratrol Against Hct116 and Hepg2 Cancer Cell Lines (Conference Paper) #

Authors

  • Wafa Nazi Shnaikat 1Faculty of Pharmacy, Al-Ahliyya Amman University, Amman, Jordan
  • Ekbal H. Ekbal H. Al-Khateeb 1Faculty of Pharmacy, Al-Ahliyya Amman University, Amman, Jordan
  • Nawfal A.M. Numan 1Faculty of Pharmacy, Al-Ahliyya Amman University, Amman, Jordan *2Current address: Department of Pharmacy, Al-Marrif University College, Anbar, Iraq
  • Manal M. Abbas
  • Ashok Shakya AL-AHLIYYA AMMAN UNIVERSITY

DOI:

https://doi.org/10.31351/vol31issSuppl.pp92-99

Keywords:

Doxorubicin, Baicalein, Resveratrol, IC50, Combination index, Cardiotoxicity.

Abstract

Combination of natural poly-phenolic compounds with chemotherapeutic agents is recently being a novel strategy in cancer therapy researches owing to their potential antioxidant and anti-inflammatory properties that modulate several intracellular signaling pathways.

Resveratrol and Baicalein are well known poly-phenolic compounds that belong to stilbene and flavone subclasses, respectively.

This study aims to investigate the possible enhancement effect of resveratrol and Baicalein when combined with doxorubicin using a different combination ratio and applied on two cancer cell lines: HCT116 (colorectal cancer cells) and HepG2 (hepatocellular cancer cells). It also investigates the possibility of such natural compounds to provide a protection effect on cardiocytes (H9C2) when resveratrol and Baicalein treatment followed by doxorubicin is used. 

The two cancer cell lines were treated with different combination groups, including the combination between doxorubicin and Baicalein or resveratrol and the combination between the three compounds using a different combination ratio for both treatment groups (i.e., two drugs or three drugs combination). Treatment applied on cells, using cell density of 7000 cells /well and incubation time was 48 hrs. MTT test was performed to assay the cell viability.

The results obtained showed that the cytotoxicity of doxorubicin in the two cancer cell lines has increased when combined with Baicalein and resveratrol. Doxorubicin IC50 decreased from 4.99 µg/ml to 0.3657 µg/ml and from 7.3 µg/ml to 0.676 µg/ml on HCT116 and HepG2 cells, respectively, using constant combination ratio (1:1:1).

The combination of doxorubicin, Baicalein, and resveratrol has resulted in a less cardiotoxic effect compared to treatment with doxorubicin alone. This decrease was obviously seen when the three compounds were combined using a low concentration range and with a constant combination ratio.

Conclusion: combinations of Baicalein and resveratrol with doxorubicin chemotherapeutic drug In Vitro had enhanced the cytotoxic activity of such a chemotherapeutic drug, while simultaneously eliminating its cardio-toxicity side effect.

 

References

Liu H, Dong Y, Gao Y, Du Z, Wang Y, Cheng P et al. The fascinating effects of baicalein on cancer: a review. International Journal of Molecular Sciences. 2016;17(10):1681.

Wang LL, Jin XH, Cai MY, Li HG, Chen JW, Wang FW et al. AGBL2 promotes cancer cell growth through IRGM-regulated autophagy and enhanced Aurora A activity in hepatocellular carcinoma. Cancer Letters. 2018;414:71-80.

Wenningmann N, Knapp M, Ande A, Vaidya TR, Ait-Oudhia S. Insights into doxorubicin-induced cardiotoxicity: molecular mechanisms, preventive strategies, and early monitoring. Molecular pharmacology. 2019;96(2):219-32.

Rawat PS, Jaiswal A, Khurana A, Bhatti JS, Navik U. Doxorubicin-induced cardiotoxicity: An update on the molecular mechanism and novel therapeutic strategies for effective management. Biomedicine & Pharmacotherapy . 2021; 139:111708.

Wang Z, Wang N, Chen J, Shen J. Emerging glycolysis targeting and drug discovery from Chinese medicine in cancer therapy. Evidence-Based Complementary and Alternative Medicine. 2012;2012.

Mansilla S, Llovera L, Portugal J. Chemotherapeutic targeting of cell death pathways. Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry-Anti-Cancer Agents). 2012; 12(3) :226 -38.

Mohammed A, Janakiram NB, Pant S, Rao CV. Molecular targeted intervention for pancreatic cancer. Cancers. 2015;7(3):1499-542.

Li B, Gan R, Yang Q, Huang J, Chen P, Wan L et al. Chinese herbal medicines as an adjunctive therapy for unresectable pancreatic cancer: a systematic review and meta-analysis. Evidence-Based Complementary and Alternative Medicine. 2015;2015.

Tsao R. Chemistry and biochemistry of dietary polyphenols. Nutrients. 2010;2(12):1231-46.

Lambert JD, Elias RJ. The antioxidant and pro-oxidant activities of green tea polyphenols: a role in cancer prevention. Archives of biochemistry and biophysics. 2010 ;501(1):65-72.

Scalbert A, Manach C, Morand C, Rémésy C, Jiménez L. Dietary polyphenols and the prevention of diseases. Critical reviews in food science and nutrition. 2005 ;45(4):287-306.

Li-Weber M. New therapeutic aspects of flavones: the anticancer properties of Scutellaria and its main active constituents Wogonin, Baicalein and Baicalin. Cancer treatment reviews. 2009 ;35(1):57-68.

Pandey KB, Rizvi SI. Plant polyphenols as dietary antioxidants in human health and disease. Oxidative medicine and cellular longevity. 2009 ;2(5):270-8.

Rocha-González HI, Ambriz-Tututi M, Granados-Soto V. Resveratrol: a natural compound with pharmacological potential in neurodegenerative diseases. CNS neuroscience & therapeutics. 2008, 14(3):234-47.

Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Advances in enzyme regulation. 1984 ;22:27-55.

Downloads

Published

2023-02-16

How to Cite

1.
Shniakat WN, Ekbal H. Al-Khateeb EH, Numan NA, Manal M. Abbas, Shakya A. Cytotoxic Evaluation of Doxorubicin Combination with Baicalein and Resveratrol Against Hct116 and Hepg2 Cancer Cell Lines (Conference Paper) #. Iraqi Journal of Pharmaceutical Sciences [Internet]. 2023 Feb. 16 [cited 2024 Nov. 19];31(Suppl.):92-9. Available from: https://bijps.uobaghdad.edu.iq/index.php/bijps/article/view/2030

Publication Dates